Phase I Trial of Circadian Patterned Infusion of Continuous IL-2 Opens

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

MANHASSET, NY--North Shore University Hospital-Cornell University Medical College has announced the start of a phase I study of continuous infusion interleukin-2 given with a circadian modified pattern (CORN 9476).

MANHASSET, NY--North Shore University Hospital-Cornell UniversityMedical College has announced the start of a phase I study ofcontinuous infusion interleukin-2 given with a circadian modifiedpattern (CORN 9476).

M. Margaret Kemeny, MD, chief, division of surgical oncology,said that the trial is open to all patients with metastatic melanomaor metastatic renal cell carcinoma except those who have alreadyreceived previous IL-2 therapy or have failed two or more chemotherapeuticor immunotherapeutic treatments.

The goals of the study are (1) to identify the optimal cycle ina 24-hour period for the administration of IL-2 as a continuousinfusion and (2) to determine whether increased amounts of IL-2are tolerated with less toxicity using this optimal pattern. Formore information, contact Dr. Kemeny at 516-562-3153.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content